Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CervoMed Inc CRVO

Healthcare Biotechnology
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its... see more

Recent & Breaking News (NDAQ:CRVO)

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 12, 2024

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

GlobeNewswire December 10, 2024

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

GlobeNewswire November 27, 2024

CervoMed Announces Key Senior Leadership Appointments

GlobeNewswire November 13, 2024

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire November 12, 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

GlobeNewswire November 8, 2024

CervoMed to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2024

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

GlobeNewswire November 4, 2024

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

GlobeNewswire October 29, 2024

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

GlobeNewswire October 15, 2024

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire October 2, 2024

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

GlobeNewswire September 26, 2024

CervoMed to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2024

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

GlobeNewswire August 22, 2024

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire August 12, 2024

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire July 30, 2024

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

GlobeNewswire July 29, 2024

CervoMed to Participate in the Emerging Growth Conference

GlobeNewswire July 17, 2024

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

GlobeNewswire July 11, 2024

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

GlobeNewswire June 24, 2024